Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2006; 12(37): 6026-6031
Published online Oct 7, 2006. doi: 10.3748/wjg.v12.i37.6026
Published online Oct 7, 2006. doi: 10.3748/wjg.v12.i37.6026
With aPCR | Without aPCR | |
(n = 8) | (n = 24) | |
Sex ratio (M/F) | 3/5 | 9/15 |
Age at diagnosis (yr) | 30 (13-53) | 31 (10-46) |
Duration of disease (mo) | 140 (86-257) | 145 (65-272) |
aPC ratio1 | 1.52 (1.19-1.64) | 2.31 (2.08-2.66) |
Patients with VTE in the history | 5 (63%)b | 2 (8%) |
Smokers | 4 (50%) | 19 (79%) |
Patients under azathioprine | 4 (50%) | 15 (63%) |
Location of CD2 | ||
Terminal ileum | 2 (25%) | 4 (17%) |
Colon | 1 (12.5%) | 5 (21%) |
Ileocolon | 4 (50%) | 12 (50%) |
Upper gastrointestinal tract | 1 (12.5%) | 3 (12%) |
- Citation: Novacek G, Miehsler W, Palkovits J, Reinisch W, Waldhör T, Kapiotis S, Gangl A, Vogelsang H. Resistance to activated protein C is a risk factor for fibrostenosis in Crohn’s disease. World J Gastroenterol 2006; 12(37): 6026-6031
- URL: https://www.wjgnet.com/1007-9327/full/v12/i37/6026.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i37.6026